The Role of Emotion in the Development of Psychopathology

NCT ID: NCT00001654

Last Updated: 2008-03-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1200 participants

Study Classification

OBSERVATIONAL

Study Start Date

1997-05-31

Study Completion Date

2003-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The dysregulated experience and expression of emotion is implicated in psychiatric disorders associated both with externalizing problems (aggressive, antisocial behaviors) and internalizing problems (anxiety, depression). Adolescence is a critical juncture in the development of these disorders because of the increased incidence and differentiation of clinical problems during this time period. This is a biobehavioral, longitudinal investigation of the role of emotion in the development of psychopathology in adolescence. The focus is on socialization experiences and biological processes that contribute to emotion dysregulation and disorder in male and female youths between 11 and 16 years of age. Groups studied include (1) comorbid externalizers and internalizers, (2) externalizers only, (3) internalizers only, and (4) asymptomatic youth. The adolescents are assessed again two years later, with instruments and paradigms similar to those used at Time 1. One theme pertains to the integration and disconnection of emotions across systems (e.g., physiological and self-report of experience), and how different patterns of emotion relate to psychopathology. A second theme pertains to development changes in how disorders are manifested (e.g., increased differentiation along gender specific pathways). The anticipated number of patient days per year is 240 for adolescents and mothers, and 120 days for fathers.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Dysregulated emotions are central features of psychiatric disorders associated with both externalizing problems (aggressive, antisocial behaviors) and internalizing problems (anxiety, depression). Adolescence is a critical juncture in the development of these disorders because of the increased incidence and differentiation of clinical problems particularly along gender-based lines. This is a biobehavioral, longitudinal investigation of the role of emotion in the development of psychopathology in adolescence. The focus is on socialization experiences and biological processes that contribute to emotion dysregulation and disorder. Younger (11-13) years) and older (14-16 years) male and female adolescents are followed over time to assess outcomes (psychiatric and psychological problems; adaptive functioning). Groups studied include (1) comorbid externalizers and internalizers, (2) externalizers, (3) internalizers, and (4) asymptomatic youth. Longitudinal analyses will examine factors that contribute to continuation, exacerbation, shifts, or improvement in symptoms over time. Time 1 data collection is complete and 30% of Time 2 cases have been seen. The current anticipated number of patient days per year is 150 for adolescents and mothers. Data collection will be completed by January, 2003.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mood Disorder

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Subjects and their families will be recruited from the community.

Inclusionary criteria will be based on mother and youth report of (a) emotion regulation problems and (b) the presence of subclinical or clinical symptomatology based on broad-band scales of the Youth Self-Report or mother's report of behavior problems.

Individuals meeting entry criteria will be offered entry into the study, and others will be notified.

Exclusion Criteria

A debilitating physical impairment (e.g., seizure disorder, cerebral palsy, head trauma).

Significant intellectual impairment (i.e., IQ less than 70).

History of psychosis.

Any condition that would impair a participant's ability to respond to the study's paradigms will be excluded from this study at the time of screening.
Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute of Mental Health (NIMH)

NIH

Sponsor Role lead

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

National Institute of Mental Health (NIMH)

Bethesda, Maryland, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Akil H, Haskett RF, Young EA, Grunhaus L, Kotun J, Weinberg V, Greden J, Watson SJ. Multiple HPA profiles in endogenous depression: effect of age and sex on cortisol and beta-endorphin. Biol Psychiatry. 1993 Jan 15;33(2):73-85. doi: 10.1016/0006-3223(93)90305-w.

Reference Type BACKGROUND
PMID: 8382535 (View on PubMed)

Angold A, Costello EJ. Depressive comorbidity in children and adolescents: empirical, theoretical, and methodological issues. Am J Psychiatry. 1993 Dec;150(12):1779-91. doi: 10.1176/ajp.150.12.1779.

Reference Type BACKGROUND
PMID: 8238631 (View on PubMed)

Anderson JC, Williams S, McGee R, Silva PA. DSM-III disorders in preadolescent children. Prevalence in a large sample from the general population. Arch Gen Psychiatry. 1987 Jan;44(1):69-76. doi: 10.1001/archpsyc.1987.01800130081010.

Reference Type BACKGROUND
PMID: 2432848 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

97-M-0116

Identifier Type: -

Identifier Source: secondary_id

970116

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.